In May, Tom Whitehead, co-founder of the Emily Whitehead Foundation, traveled to Long Beach, Calif., to participate in the 2019 PDA Cell and Gene Therapy Conference.

At the conference, he spoke in the opening plenary about his family’s experience with a CAR-T (chimeric antigen receptor) cell therapy and how the treatment affects the patient’s experience, both during and after administration. In 2012, his daughter Emily was the first child to receive a CAR-T cancer treatment that totally eradicated her cancer. She is currently seven years cancer-free.

The Foundation thanks Michael Blackton, the moderator of the panel, PDA staff member Brooke Schneider, and the entire PDA committee for the invitation to participate, as well as ValSource for sponsoring the session Tom spoke in!

For more information, visit the Emily Whitehead Foundation website.